- KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone or with daratumumab and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. ... Read More
Kd twice weekly dosing
Target the 56 mg/m2 dose for the best chance of achieving outcomes observed in the clinical trial1
Consecutive-day dosing schedule1
- Administer a priming dose of KYPROLIS® (20 mg/m2) on Days 1 and 2 of Cycle 1 as a 30-minute intravenous infusion to evaluate tolerability to treatment with KYPROLIS®
- Target the therapeutic dose of KYPROLIS® (56 mg/m2) starting on Day 8 of Cycle 1 if the priming dose is tolerated on Days 1 and 2 of Cycle 1
- Administer KYPROLIS® (56 mg/m2) as a 30-minute intravenous infusion on 2 consecutive days each week for 3 weeks followed by a 12-day rest period as part of a 28-day treatment cycle
- Treatment may be continued until disease progression or until unacceptable toxicity occurs
IMiD-FREE
Kd TWICE WEEKLY
Priming dose
Therapeutic dose
Days 1 and 2
of Cycle 1 only
20
mg/m2
All subsequent doses
if tolerated
56
mg/m2
Dosing rationale
Preclinical studies demonstrated that consecutive-day dosing of KYPROLIS® suppressed recovery of proteasome activity between doses. Proteasome inhibition was maintained for ≥ 48 hours following the first dose of KYPROLIS® for each week of dosing. The clinical significance of preclinical studies is unknown.1,2
Modify dosing based on toxicity. Refer to the full Prescribing Information and Dosing and Administration Guide for more information.1
Cycle 1
In Cycle 1, the 20 mg/m2 priming dose is used for Days 1 and 2 to evaluate tolerability1
Target the 56 mg/m2 dose of KYPROLIS® starting on Day 8 of Cycle 1 if the priming dose is tolerated on Days 1 and 2 of Cycle 1.1
Cycle 2+
In Cycle 2 and beyond, the targeted label dose of KYPROLIS® is 56 mg/m2 as tolerated1,*
Select administration precautions: Adequate hydration is required1
Adequate hydration is required prior to dosing in Cycle 1, especially in patients at high risk of tumor lysis syndrome or renal toxicity.
- The recommended hydration includes both oral fluids (30 mL per kg at least 48 hours before Cycle 1, Day 1) and IV fluids (250 mL to 500 mL of appropriate IV fluid prior to each dose in Cycle 1)
- If needed, give an additional 250 mL to 500 mL of intravenous fluids following KYPROLIS® administration
- Continue oral and/or intravenous hydration, as needed, in subsequent cycles
- Monitor patients for evidence of volume overload and adjust hydration to individual patient needs, especially in patients with or at risk for cardiac failure